Helsinn Group announces the appointment of Paul Rittman as Chief Executive Officer, Helsinn Therapeutics (HTU) 28 February 2018
US Court of Appeals for Federal Circuit Rejects Petition by Helsinn for Rehearing En Banc of Federal Circuit Panel Ruling That Certain Patents Covering Aloxi® in the US Market Are Invalid 18 January 2018
Helsinn Group and MEI Pharma Announce that Pracinostat has Received Orphan Drug Designation from the European Medicines Agency for the Treatment of acute myeloid leukemia (AML) 12 January 2018
A call for action to patient entrepreneurs in the area of cancer to compete at the Lyfebulb-Helsinn Summit for the first ever Lyfebulb- Helsinn Innovation Award 9 January 2018
Helsinn to honor Anna Braglia Endowed Young Investigator Award recipient at Helsinn reception during JP Morgan Healthcare Conference 2018 8 January 2018
Helsinn Group supports Satellite Symposium at 10th International Conference on Cachexia, Sarcopenia and Muscle Wasting 5 December 2017
Linkedin